Monoclonal antibodies in the internal medicine
Authors:
Kristína Brázdilová; Daniel Čierny; Zdenko Killinger; Peter Jackuliak; Juraj Payer
Authors place of work:
V. interná klinika LF UK a UN Bratislava, Nemocnica Ružinov
Published in the journal:
AtheroRev 2016; 1(2): 65-68
Category:
Reviews
Summary
New findings in the field of pathogenesis of autoimmune diseases and cancer, as well as progress in the development of biomedical technologies have enabled the development of new and in particular more precisely targeted forms of therapy of different diseases. The common characteristic of these drugs referred to as biological treatment is their targeted intervention into the individual etiopathogenetic processes which occur in the damaged organism. These distinctive effects of theirs are produced by means of highly active substances of biological nature marked by a high specificity of effect and acting on a precisely defined target. At present we know and also use quite a large number of preparations in Slovakia that are effectively utilized in the treatment of different diseases in various fields of internal medicine.
Key words:
biological treatment – monoclonal antibodies
Zdroje
1. Killinger Z, Čierny D, Brázdilová K et al. Biologická liečba reumatoidnej artritídy. Via Pract 2009; 6(9): 342–346.
2. Cush J, Kavanaugh A. TNF-alfa blocking therapies. In: Hochberg M, Silman AJ, Smolen J (eds). Rheumatology. 2 Voll. 4th ed. Elsevier: London 2008. ASIN: B011DBW7F0.
3. Ostor AJK. Anti-cytokine biologics. In: Watts RA, Conaghan PG, Denton Ch et al (eds). Oxford textbook of rheumatology. 4th ed. OUP (Oxford University Press): Oxford 2013: 636–641. ISBN 978–0199642489.
4. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9(3): 269–277.
5. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12(13–14): 540–547.
6. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008; 77(3): 311–319.
7. Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm 2004; 61(7): 695–708.
8. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84(5): 548–558.
9. Sleeman MA. Thematic issue: Rheumatology: An evolutionary force in biologics. Curr Pharm Des 2015; 21(17): 2168–2169.
10. Kriška M, Rovenský J. Stratégie hodnotenia rizika biologických liekov s aspektom na reumatoidnú artritídu. Klin Farmakol Farm 2013; 27(2): 80–83.
11. Hui-Yuen JS, Reddy A, Taylor J et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol 2015; 42(12): 2288–2295.
12. Gossec L, Smolen JS. Treatment of psoriatic arthritis: management recommendations. Clin Exp Rheumatol 2015; 33(5): 73–77.
13. Sýkora J. Denosumab – nová monoklonálna protilátka na liečbu osteoporózy. Farm Obzor 2011; 80(1): 25–35.
14. Payer J, Jackuliak P, Kollerová J et al. Prevencia a liečba osteoporózy. In: Payer J, Killinger Z (eds). Osteoporóza. Herba: Bratislava 2012: 203–205. ISBN 978–80–89171–94–1.
15. Adams GP, Welner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23(9): 1147–1157.
16. Mardiak J. Cielená liečba v onkológii. Klin Farmakol Farm 2008; 22(2): 64–67.
17. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1–18.
18. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012; 51(Suppl 6): viI37-vi43. Dostupné z DOI: <http://doi: 10.1093/rheumatology/kes283>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2016 Číslo 2
- Memantine Eases Daily Life for Patients and Caregivers
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
Najčítanejšie v tomto čísle
- Monoclonal antibodies in the internal medicine
- Diabetes mellitus and lipid metabolism
- Alirocumab, Praluent® in the light of studies
- LDL-cholesterol – the main risk factor for atherosclerosis